Relevant bibliographies by topics / Breast Cancer Control

Academic literature on the topic 'Breast Cancer Control'

Author: Grafiati
Published: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Breast Cancer Control.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Breast Cancer Control"

1

Marino, Natascia, Rana German, Nakshatri Harikrishna, Ram Podicheti, Ashley Vode, Jun Liu, Jie Huang, Douglas B. Rusch, Sha Cao, and Anna Maria Storniolo. "Epigenetic control of breast cancer susceptibility." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 1560. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1560.

Full text
Abstract:
1560 Background: Epigenetic mechanisms such as DNA methylation are important regulators of gene expression and are frequently dysregulated early in breast carcinogenesis. The relationship between DNA methylation aberrations in normal breast tissue and breast cancer risk remains unclear. Methods: Disease-free breast tissue cores donated by 71 high-risk (Tyrer-Cuzick lifetime risk ≥20%) and 79 average-risk women were obtained from the Komen Tissue Bank and processed for whole methylome (Diagenode's MethylCap Library and single-end 75-bp sequencing on Illumina Nextseq) and whole transcriptome (Illumina Nextseq) profiling. Reads from RNA-seq data were aligned to the human genome reference, GRCh38.p12 using STAR v.2.5.2b and tested for differential gene expression using DESeq2 ver. 1.24.0. For DNA methylation data, difference of variation in deduplicated read coverage among 250-bp fixed sized bins spanning CpG islands between high- and average-risk libraries was computed as z-ratios to identify differentially methylated regions. Pathway analysis was performed using IPA v06_01. Results: We identified 1355 CpGs that were differentially methylated between high- and average-risk breast tissues (ΔZ > 0.5, FDR < 0.05). Hypomethylated CpGs were overrepresented in high-risk tissue and were found predominantly (68%) in non-coding regions. Hypermethylated CpG sites were found equally in the gene body and non-coding regions. Transcriptomic analysis identified 112 differentially expressed genes (fold change≥2, FDR < 0.05), involved in chemokines signaling, metabolism and estrogen biosynthesis. Among those, FAM83A (logfc = 2.3, FDR = 0.004) was previously described as epigenetically dysregulated in multiple cancers and transforms breast epithelial cell in vitro. Methylation-expression correlations revealed 11 epigenetically regulated genes including cellular transformation-associated BMPR1B. Two hypomethylated/upregulated long non-coding RNAs were also identified in high-risk breasts. Conclusions: This is the first gene expression/DNA methylation analysis of normal breasts from women at either high or average risk of breast cancer. Our discovery of epigenetically regulated genes associated with breast cancer risk provides an opportunity to mechanistically dissect breast cancer susceptibility and risk-associated molecular alterations. Unlike the current focus of identifying germline mutations or single nucleotide polymorphisms responsible for higher risk, our studies reveal an epigenetic mechanism, which is not discernable through simple genomic sequencing.
APA, Harvard, Vancouver, ISO, and other styles
2

Mendonça, Gulnar Azevedo S., and José Eluf-Neto. "Hospital visitors as controls in case-control studies." Revista de Saúde Pública 35, no. 5 (October 2001): 436–42. http://dx.doi.org/10.1590/s0034-89102001000500005.

Full text
Abstract:
OBJECTIVE: Selecting controls is one of the most difficult tasks in the design of case-control studies. Hospital controls may be inadequate and random controls drawn from the base population may be unavailable. The aim was to assess the use of hospital visitors as controls in a case-control study on the association of organochlorinated compounds and other risk factors for breast cancer conducted in the main hospital of the "Instituto Nacional de Câncer" -- INCA (National Cancer Institute) in Rio de Janeiro (Brazil). METHODS: The study included 177 incident cases and 377 controls recruited among female visitors. Three different models of control group composition were compared: Model 1, with all selected visitors; Model 2, excluding women visiting relatives with breast cancer; and Model 3, excluding all women visiting relatives with any type of cancer. Odds ratios (OR) and 95% confidence intervals were calculated to test the associations. RESULTS: Age-adjusted OR for breast cancer associated with risk factors other than family history of cancer, except smoking and breast size, were similar in the three models. Regarding family history of all cancers, except for breast cancer, there was a decreased risk in Models 1 and 2, while in Model 3 there was an increased risk, but not statistically significant. Family history of breast cancer was a risk factor in Models 2 and 3, but no association was found in Model 1. In multivariate analysis a significant risk of breast cancer was found when there was a family history of breast cancer in Models 2 and 3 but not in Model 1. CONCLUSIONS: These results indicate that while investigating risk factors unrelated to family history of cancer, the use of hospital visitors as controls may be a valid and feasible alternative.
APA, Harvard, Vancouver, ISO, and other styles
3

Vega Avalos, Jorge Hermilo, Luis Enrique Hernández, Laura Yareni Zuñiga, María Guadalupe Sánchez-Parada, Ana Elizabeth González Santiago, Luis Miguel Román Pintos, Rolando Castañeda Arellano, et al. "Mitochondrial Control Region Variants Related to Breast Cancer." Genes 13, no. 11 (October 27, 2022): 1962. http://dx.doi.org/10.3390/genes13111962.

Full text
Abstract:
Breast cancer has an important incidence in the worldwide female population. Although alterations in the mitochondrial genome probably play an important role in carcinogenesis, the actual evidence is ambiguous and inconclusive. Our purpose was to explore differences in mitochondrial sequences of cases with breast cancer compared with control samples from different origins. We identified 124 mtDNA sequences associated with breast cancer cases, of which 86 were complete and 38 were partial sequences. Of these 86 complete sequences, 52 belonged to patients with a confirmed diagnosis of breast cancer, and 34 sequences were obtained from healthy mammary tissue of the same patients used as controls. From the mtDNA analysis, two polymorphisms with significant statistical differences were found: m.310del (rs869289246) in 34.6% (27/78) of breast cancer cases and 61.7% (21/34) in the controls; and m.315dup (rs369786048) in 60.2% (47/78) of breast cancer cases and 38.2% (13/34) in the controls. In addition, the variant m.16519T>C (rs3937033) was found in 59% of the control sequences and 52% of the breast cancer sequences with a significant statistical difference. Polymorphic changes are evolutionarily related to the haplogroup H of Indo-European and Euro-Asiatic origins; however, they were found in all non-European breast cancers.
APA, Harvard, Vancouver, ISO, and other styles
4

Patterson, Cam, and Sarah Ronnebaum. "Breast cancer quality control." Nature Cell Biology 11, no. 3 (March 2009): 239–41. http://dx.doi.org/10.1038/ncb0309-239.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dai, Xiaofeng, Rong Ma, Xijiang Zhao, and Fengfeng Zhou. "Epigenetic profiles capturing breast cancer stemness for triple negative breast cancer control." Epigenomics 11, no. 16 (December 2019): 1811–25. http://dx.doi.org/10.2217/epi-2019-0266.

Full text
Abstract:
Aim: Triple-negative breast cancers (TNBCs) contain a higher percentage of breast cancer stem cells (BCSCs) than the other subtypes and lack effective yet safe-targeted therapies. We would like to unveil genes relevant to the therapeutic control of breast cancer stemness at the epigenetic level. Methods: We sequenced the transcriptome of BCSCs isolated from TNBCs, identified genes differentially expressed in these cells and subjected to DNA methylation and established the Bayesian network as well as interactions out of them. Results & conclusion: We presented a core epigenetic BCSC gene panel consisting of eight genes that can be used for BCSCs and TNBCs identification, and revealed the dominant roles of FOXA1 and GATA3 in orchestrating breast cancer heterogeneity and stemness.
APA, Harvard, Vancouver, ISO, and other styles
6

Kaushal, Arjita. "Breast Cancer in Women, Signs and Treatment Approaches." NewBioWorld 2, no. 1 (January 10, 2020): 25–27. http://dx.doi.org/10.52228/nbw-jaab.2020-2-1-5.

Full text
Abstract:
Cancer starts when cells start to grow out of control. Here we talk about breast cancer which starts in the breast hence the name. It is the second most common cause of death of cancer among women all over the world. Occur mostly in women but also in men. 5-10% of breast cancers are directly linked to generational mutations, parts of the breast that start breast cancer, such as lobules, ducts, and nipples. There are many types of treatment they have their pros and cons. Some tests that examine the breasts are used to diagnose breast cancer, like physical examination and health history, clinical breast exam, and mammogram, for treatment surgeries, therapies, etc. Treatment is recommended based on stages: stage 1, stage 2, stage 3, and stage 4.
APA, Harvard, Vancouver, ISO, and other styles
7

Mettlin, Curtis. "Breast cancer risk factors. Contributions to planning breast cancer control." Cancer 69, S7 (April 1, 1992): 1904–10. http://dx.doi.org/10.1002/1097-0142(19920401)69:7+<1904::aid-cncr2820691705>3.0.co;2-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Boyages, John. "Interview: Breast cancer: taking control." Breast Cancer Management 2, no. 2 (March 2013): 105–7. http://dx.doi.org/10.2217/bmt.13.8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

McGuire, William L., Kathleen M. Foley, Michael H. Levy, and C. Kent Osborne. "Pain control in breast cancer." Breast Cancer Research and Treatment 13, no. 1 (January 1989): 5–15. http://dx.doi.org/10.1007/bf01806545.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zujewski, Jo Anne, Allison L. Dvaladze, Andre Ilbawi, Benjamin O. Anderson, Silvana Luciani, Lisa Stevens, and Julie Torode. "Knowledge Summaries for Comprehensive Breast Cancer Control." Journal of Global Oncology, no. 4 (December 2018): 1–7. http://dx.doi.org/10.1200/jgo.17.00141.

Full text
Abstract:
Breast cancer is the most common cancer in women worldwide, affecting > 1.6 million women each year, projected to increase to 2.2 million cases annually by 2025. A disproportionate number of the > 500,000 women who die as a result of breast cancer each year reside in low-resource settings. Breast cancer control is an important component of cancer control planning and women’s health programs, and tools are needed across the care continuum to reduce the cancer burden, especially in low-resource settings. Cancer control planning is complex and multifaceted. Evidence shows that outcomes are improved when prevention, early diagnosis, treatment, and palliation are integrated and synchronously developed within a country/region’s health plan. The Knowledge Summaries for Comprehensive Breast Cancer Control are the product of a multiyear collaboration led by the Union for International Cancer Control, Breast Health Global Initiative, Pan American Health Organization, and Center for Global Health of the US National Cancer Institute. Fourteen knowledge summaries distilled from evidence-based, resource-stratified guidelines, and aligned with WHO guidance on breast cancer control, build a framework for resource prioritization pathways and delivery systems for breast cancer control at four levels of available resources: basic, limited, enhanced, and maximal. Each summary contains relevant content to inform breast cancer policy, clinical care, and advocacy, aiding in the development and implementation of policies and programs. These tools provide a common platform for stakeholders, including policymakers, administrators, clinicians, and advocates to engage in decision making appropriate to their local setting. The goal is to facilitate evidence-based policy actions and urgently advance implementation of an integrated approach to reduce breast cancer mortality and improve quality of life.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Breast Cancer Control"

1

Tang, Mei-Tzu Chen. "Induced abortion and risk of breast cancer /." Thesis, Connect to this title online; UW restricted, 1998. http://hdl.handle.net/1773/10929.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Swartz, Esti. "Emotional intelligence and locus of control of adult breast cancer patients receiving treatment." Thesis, Nelson Mandela Metropolitan University, 2010. http://hdl.handle.net/10948/d1015686.

Full text
Abstract:
Breast cancer is the most prevalent cancer of women in South Africa, with one in twenty-seven women diagnosed with breast cancer in their lifetime. By building on human strengths, ways can be found to cope effectively with adversity. This will contribute to psychological well-being and result in living constructive and meaningful lives. Emotional intelligence and locus of control are two constructs which, according to previous research, may be associated with psychological wellbeing. Limited research has been conducted on these constructs in populations facing adversity. Adaptation to breast cancer treatment is considered to be an extremely difficult process. The research aimed to explore and describe emotional intelligence and locus of control within an adult breast cancer population. A sample of 67 breast cancer patients receiving treatment was approached to complete a biographical questionnaire and two pencil-and-paper questionnaires. Descriptive and inferential statistics were be used to analyze the data. The results of the quantitative analysis indicated a significant negative correlation between emotional intelligence and locus of control which shows that patients with higher levels of emotional intelligence possess more internal locus of control orientations, while patients with lower emotional intelligence possess more external locus of control orientations. The population presented with above average emotional intelligence and an internal locus of control orientation. The study can be regarded as the first step in opening a field of research which could contribute to more effective coping and the overall psychological well-being of individuals facing adversity in South Africa. Furthermore, the findings of the study contributed to understanding the role of emotional intelligence and locus of control in these populations and encouraged further research and the development and implementation of programmes that promote skills development in these areas.
APA, Harvard, Vancouver, ISO, and other styles
3

Rohan, Thomas Edward. "Diet, hormones and breast cancer : a case-control study in women /." Title page, table of contents, summary and appendices only, 1986. http://web4.library.adelaide.edu.au/theses/09PH/09phr7373.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hong, Deli. "RUNX1 Control of Mammary Epithelial and Breast Cancer Cell Phenotypes." eScholarship@UMMS, 2017. https://escholarship.umassmed.edu/gsbs_diss/949.

Full text
Abstract:
Breast cancer remains the most common malignant disease in women worldwide. Despite the advantages of early detection and improved treatments, studies into the mechanisms that initiate and drive breast cancer progression are still required. Recent studies have identified RUNX1, which is an essential transcription factor for hematopoiesis, is one of the most frequently mutated genes in breast cancer patients. However, the role of RUNX1 in the mammary gland is understudied. In this dissertation, we examined the role of RUNX1 in both normal mammary epithelial and breast cancer cells. Our in vitro studies demonstrated that RUNX1 inhibits epithelial to mesenchymal transition (EMT), migration, and invasion, reflecting its tumor suppressor activity, which was confirmed in vivo. Moreover, RUNX1 also contributes significantly to inhibition of the phenotypes of breast cancer stem cells (CSC), which is responsible for metastasis and tumor relapse. We showed that Runx1 overexpression reduces the tumorsphere formation and cancer stem cell population. Overall, our studies provide mechanistic evidence for RUNX1 repression of EMT in mammary cells, anti-tumor activity in vivo and regulation of CSC-like properties in breast cancer. Our results highlight crucial roles for RUNX1 in preventing epithelial to mesenchymal transition and tumor progression in breast cancer. This RUNX1 mediated mechanism points to novel intervention strategies for early stage breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
5

Yassaee, Vahid Reza. "Towards a general strategy for breast cancer : investigation of germline mutations of BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer." Thesis, University of Sheffield, 2002. http://etheses.whiterose.ac.uk/5987/.

Full text
Abstract:
Breast cancer is the most common female malignancy and a major cause of death in middle-aged women. It results from genetic and environmental factors leading to the accumulation of mutations in essential genes, BRCA 1and BRCA2. To date, germline mutations in the BRCAI and BRCA2 genes in patients with early-onset breast and/or ovarian cancer have not been identified within the Iranian population. This study was set for two main purposes, in first for a cohort study of selected population (Iranian women) with early-onset breast cancer and secondly to evaluate and improve upon existing mutation detection techniques with respect to the BRCA genes. With the collaboration of two main centres for cancer research and treatment in Tehran-Iran, clinical information, family history and peripheral blood were obtained from 96 unrelated families for scanning of germline mutations in the BRCA 1 and BRCA2 genes. These sets of samples consists of 104 women under the age of forty-five, 88 patients affected with early-onset breast cancer or ovarian cancer and 16 unaffected individuals with strong family history of breast and/or ovary cancer. BRCA1 exons 11 and BRCA2 exons 10 and 11 by the Protein Truncation Test (PTT) and BRCAI exons 2, 3, 5, 13 and 20 and BRCA2 exons 9, 17,18 and 23 with the Single Strand Conformation Polymorphism (SSCP)assay were analysed on genomic DNA amplified by polymerase chain reaction. Ten sequence variants were identified: five are frame shift (putative mutations-four novel); three missense changes of unknown significant and two polymorphisms, one seen [BRCA2 (IVSI6-14T>C)] commonly in both Iranian and British population. Identification of these novel mutations suggests that any given population should develop a mutation database for its breast cancer screening. The pattern of mutations seen in the BRCA genes does not appear to differ from other populations studied. Early-onset breast cancer (less than 45 years) and a limited family history is sufficient to justify mutation screening with a detection rate of over 250/0 in this group, whereas sporadic early-onset breast cancer (detection rate less than 5%) is unlikely to be cost-effective. To address the penetrance and mutation spectrum of germline mutation of the contributed genes within Iranian population further studies should be performed. Meta-PCR technique was evaluated for its implication of BRCA genes scanning. Three distinct sets of BRCA gene fragments were selected to assemble with different approach for downstream analysis: the first set consisted ofBReA1 exons 2, 20 and BRCA2 exon 18 and their subsequent analysis by Protein Truncation Test; the second set comprised BRCAI exons 2, 20, 23 and 24 and their subsequent analysis by direct sequencing; and the last one contained six key coding regions from the BRCA genes, the 5' and 3'termini of exon 11 from both BRCAI and BRCA2 genes and exons 2 and 20 from BRCAI. Downstream analysis of Meta-PCR products by Protein Truncation Test was used rather than direct nucleotide sequencing because the total assembled above fragments size (~2.8kb) is sufficiently big to ignore analysing by the latter approach. PTT and direct sequencing were chosen because of their high sensitivity and specificity. These three trials were performed successfully suggesting that it may be possible to assemble the entire of coding regions of BRCAI and BRCA2 genes in a multi-step procedure.
APA, Harvard, Vancouver, ISO, and other styles
6

Caldon, Catherine Elizabeth Garvan Institute of Medical Research Faculty of Medicine UNSW. "Cell cycle control by ID1 and WT1 in breast cancer cells." Awarded by:University of New South Wales. Garvan Institute of Medical Research, 2007. http://handle.unsw.edu.au/1959.4/33125.

Full text
Abstract:
Loss of proliferative control is a cornerstone of cancer development, induced by deregulation of mitogenic signalling, insensitivity to anti-proliferative signals and direct changes in cell cycle proteins. In breast cancer these alterations are frequently targeted through cyclins D1 and E, leading to defects in G1/S transition. I have investigated the role of two potential pro-proliferative oncogenes in breast cancer, id1 andwt1. Each protein promotes proliferation in distinct contexts, with unique consquences for breast cancer cells. Using a 3D culture model of non-transformed mammary epithelial cells, I identified that id1 undergoes downregulation via rapid proteosomal degradation and cytoplasmic relocalisation during mammary epithelial morphogenesis. Overexpression of Id1 led to an increase in acinar size via an increase in S phase, and wa dependent on the presence of an intact HLH domain in Id1. Co-expression with the proto-oncogene Bcl2 led to a more disorganised acinar structure, indicating that Id1 overexpression primed the cells for further oncogenic insult. Further, Id1 overexpression was unable to increase acinar size in cyclin D1-/- acini, indicating that Id1 is dependent on cyclin D1 for its proliferative effects. Overall these data identified Id1 as capable of altering the proliferation of normal mammary epithelial cells, a crucial step in early breast carcinogenesis. Wt1 was originally identified as a tumour suppressor, but our data lends support to Wt1 acting as an oncogene in breast cancer. Wt1 is expressed highly in a range of breast cancer cell lines, and is strongly regulated by progestins. Using siRNA, we identified that Wt1 is likely to be a molecular intermediary of progestin as the downregulation of Wt1 mimics a subset of progestin effects on cell proliferation and lipid synthesis. Conversely, the overexpression of the major Wt1 isoform, Wt1 (+/+), led to attenuation of progestin-induced differentiation and growth arrest via maintenance of cyclin D1 levels. The effects of Wt1 overexpression were specific to progestins, and did not affect the actions of anti-estrogens or androgens. Consequently the overexpression of Wt1 (+/+) may disrupt the endocrine response in mammary epithelial cells, and contribute to excess proliferation and failure to differentiate during breast oncogenesis.
APA, Harvard, Vancouver, ISO, and other styles
7

Lindahl, Thomas. "Prognostic markers in breast cancer associated with cell cycle control, proliferation and angiogenesis /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7349-860-2/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Levy, Anita Rochelle. "Progestin receptor heterogeneity in a breast cancer cell line." Thesis, Rhodes University, 1995. http://hdl.handle.net/10962/d1004100.

Full text
Abstract:
Anti-oestrogens act via the oestrogen receptor whether they compete with the hormone for binding to the receptor and therefore interfere with DNA binding or inhibit transcriptional activity. These receptors exist as a large 85 complex and/or a small 45 form on sucrose density gradients. High performance ion-exchange chromatography has confirmed that the oestrogen and progestin complex is present in various isoforms. Progestin receptor heterogeneity could be influenced by the presence of oestrogens and anti-oestrogens in the culture media of hormone-dependent neoplastic cells. Cell culture methods offer the opportunity to test effects of specified components in repeated experiments on a homogeneous population of cells. MCF-7 and T47-D human breast cancer cell lines were conditioned to grow in a serum-free environment. There was no difference in cell proliferation rates, nor in their oestrogen or progestin receptor levels when compared to the same cells grown in conventional media. Receptors were present mainly in the large molecular 85 form. Both the MCF-7 and T47-D breast cancer cells showed an increase in proliferation rate with the addition of oestrogen or diethylstilbestrol. There was a corresponding loss of progestin receptor levels and an alteration in the high performance ion-exchange isoforms. Flow cytometry confirmed differences in the S-phase components of the cells following exposure to oestrogens. The proliferation rates of the cell lines as well as their progestin receptor levels decreased when treated with tamoxifen or the hydroxylated tamoxifen. There were marked changes on high performance ion-exchange chromatography profiles. DNA ploidy and S-phase showed signs of toxicity and there was an increase in cellular debris. The MCF-7 and T47-D human breast cancer cell line retained response to antioestrogen saturation.
APA, Harvard, Vancouver, ISO, and other styles
9

Veer, Pieter van 't. "Dietary habits and breast cancer a case-control study in the Netherlands /." [Maastricht : Maastricht : Rijksuniversiteit Limburg] ; University Library, Maastricht University [Host], 1990. http://arno.unimaas.nl/show.cgi?fid=5573.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bonilla, Carolina, Bernardo Bertoni, Pedro C. Hidalgo, Nora Artagaveytia, Elizabeth Ackermann, Isabel Barreto, Paula Cancela, et al. "Breast cancer risk and genetic ancestry: a case-control study in Uruguay." BioMed Central Ltd, 2015. http://hdl.handle.net/10150/610306.

Full text
Abstract:
BACKGROUND: Uruguay exhibits one of the highest rates of breast cancer in Latin America, similar to those of developed nations, the reasons for which are not completely understood. In this study we investigated the effect that ancestral background has on breast cancer susceptibility among Uruguayan women. METHODS: We carried out a case-control study of 328 (164 cases, 164 controls) women enrolled in public hospitals and private clinics across the country. We estimated ancestral proportions using a panel of nuclear and mitochondrial ancestry informative markers (AIMs) and tested their association with breast cancer risk. RESULTS: Nuclear individual ancestry in cases was (mean ± SD) 9.8 ± 7.6% African, 13.2 ± 10.2% Native American and 77.1 ± 13.1% European, and in controls 9.1 ± 7.5% African, 14.7 ± 11.2% Native American and 76.2 ± 14.2% European. There was no evidence of a difference in nuclear or mitochondrial ancestry between cases and controls. However, European mitochondrial haplogroup H was associated with breast cancer (OR = 2.0; 95% CI 1.1, 3.5). CONCLUSIONS: We have not found evidence that overall genetic ancestry differs between breast cancer patients and controls in Uruguay but we detected an association of the disease with a European mitochondrial lineage, which warrants further investigation.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Breast Cancer Control"

1

Breast cancer: Taking control. Sydney, Australia: Boycare Publishing, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dervan, Peter A. Understanding breast cancer. Jefferson, N.C: McFarland, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

MRCGP, Humphreys John, Cancer Research Campaign (Great Britain), and National Breast Screening Programme (Great Britain), eds. Breast cancer screening. Oxford: Oxford University Press, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Johnson, Edwin T. Breast cancer, Black woman. 2nd ed. Montgomery, Ala: Van Slyke & Bray, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Johnson, Edwin T. Breast cancer, black woman. Montgomery, Ala: Van Slyke & Bray, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

E, Day N., and Miller A. B, eds. Screening for breast cancer. Toronto: Huber, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1929-, Balaban Barbara, ed. The breast cancer handbook: Taking control after you've found a lump. New York, NY: HarperPerennial, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fentiman, Ian S. Prevention of breast cancer. Austin, TX: R.G. Landes, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gebbie, Kristine M. Washington cancer control plan: Smoking-related, breast, and cervical cancer. Olympia, Wash: Washington State Dept. of Health, Office of Heart Disease and Cancer Prevention, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Clarke, Pelton Taffy, and Vint Vinton C, eds. How to prevent breast cancer. New York: Simon & Schuster, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Breast Cancer Control"

1

Narod, Steven A. "Risk Assessment in Hereditary Breast Cancer." In Familial Cancer Control, 95–97. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77582-6_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Roy, Madhumita, Jaydip Biswas, and Amitava Datta. "Breast Cancer Therapy and Control." In Genetics and Epigenetics of Breast Cancer, 59–87. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-9925-3_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Samant, Rajeev S., Oystein Fodstad, and Lalita A. Shevde. "The genetic control of breast cancer metastasis." In Metastasis of Breast Cancer, 7–30. Dordrecht: Springer Netherlands, 2007. http://dx.doi.org/10.1007/978-1-4020-5867-7_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kirkpatrick, Alistair E. "Quality Control in Mammography." In Breast Cancer Screening in Europe, 143–48. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-78154-4_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Russo, Jose, and Irma H. Russo. "Endocrine Control of Breast Development." In Molecular Basis of Breast Cancer, 49–88. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18736-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Blackwell, Richard E., and Karen R. Hammond. "Hormonal Control of Normal Breast Morphology and Function." In Endocrinology of Breast Cancer, 3–20. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-699-7_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sonnenschein, Carlos, and Ana M. Soto. "Cell proliferation in metazoans: Negative control mechanisms." In Regulatory Mechanisms in Breast Cancer, 171–94. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3940-7_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Desai, P. B. "Priorities in Cancer Control Strategies in India." In Fundamental Problems in Breast Cancer, 391–99. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-2049-4_43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tabár, L. "The Role of Mammographic Screening in the Control of Breast Cancer: An Overview." In High-Risk Breast Cancer, 253–61. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-73718-3_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wanat, Karolyn A., Kelly E. Quinley, and Carrie L. Kovarik. "Telemedicine in Cancer Control Programs in Developing Countries." In Breast and Gynecological Cancers, 285–99. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-1876-4_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Breast Cancer Control"

1

Souza, Fabiana Lúcia de Lima, Francielle Souza Silva Lopes, Hellen Karine Paes Porto, and Cesar Augusto Sam Tiago Vilanova Costa. "TRIPLE-NEGATIVE BREAST CANCER AND BRCA1 UNDEREXPRESSION ASSOCIATION: AN EVIDENCEBASED META-ANALYSIS OF CASE–CONTROL STUDIES." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2010.

Full text
Abstract:
Objectives: This meta-analysis aims to evaluate the association of triple-negative breast cancer and BRCA1 gene underexpression by means of a meta-analysis. Methodology: Case–control studies, published between the years 2011 and 2015, were selected from three available databases (PubMed, Scopus, and Web of Science) and were analyzed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. Literature search was performed using the key words “([triple-negative breast cancer] AND [BRCA1] AND [Associated] AND [expression]).” Study quality was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE). The quality of evidence of the studies was classified into four categories: high, moderate, low, or very low quality. We also analyzed the influence of possible conflicts of interest and any information on ethical approval of the studies. Results: A total of 11 studies, out of the 189 studies initially identified, were included in this meta-analysis after applying the inclusion and exclusion criteria. Results show a high prevalence of BRCA1 mutations and underexpression on triple-negative breast cancer patients (χ2 =33.814 and p=0.0001). Studies also show that chemotherapy remains the basis of systemic treatment for breast cancer patients with the BRCA1 mutations and after triple-negative breast cancer treatment, tumor recurrence and resistance to therapy remain a challenging problem. Conclusion: This meta-analysis corroborates other studies that the underexpressive BRCA1 carriers are linked to a higher risk to develop breast cancers that tend to be negative for estrogen (ER), progesterone (PgR), and HER-2 receptor (triple-negative).
APA, Harvard, Vancouver, ISO, and other styles
2

Costa, Amanda G., Alícia M. V. Medina, Idam de Oliveira Junior, Edmundo C. Mauad, and René A. C. Vieira. "BARRIERS RELATED TO MAMMOGRAPHY IN THE RIVERSIDE POPULATION OF THE BRAZILIAN AMAZON: CASE-CONTROL STUDY." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1ep02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mota, Jordana C. M. Godinho, Larissa V. Gonçalves, João F. Mota, Raquel M. Schincaglia, Karine A. Martins, and Ruffo Freitas Junior. "INFLUENCE OF LIFESTYLE FACTORS ON BREAST CANCER RISK: A CASE-CONTROL STUDY WITH A REPRESENTATIVE SAMPLE OF THE BRAZILIAN POPULATION." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1cp01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Oliveira, Ilse Franco de, Camila Leal Diniz, Rosemar Macedo de Souza Rahal, Macks Wendhell Gonçalves, Cristina Pinto Naldi Ruiz, Marcelo Vilela Lauar, Paulinelly Messias de Almeida, and Ruffo Freitas-Junior. "PREVALENCE STUDY OF CLINICAL INDICATIONS FOR BREAST MRI." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2068.

Full text
Abstract:
Objective: This is a cross-sectional study of the clinical indications and prevalence of breast magnetic resonance scan. Methods: Data were collected retrospectively from women who had breast MRI performed at the Clínica São Marcelo and who agreed to participate in the study during the period 2020–2021. The data were extracted from the anamneses and respective medical reports of 308 women who had breast MRI scans and analyzed using the SPSS statistical software version 26.0. Results: The predominant age group was 40–49 years with a relative frequency of 34.9%, followed by 50–59 years representing 26.7%, women over 60 years with a frequency of 19.9% and 18–39 years with a relative frequency of 18.6%. Regarding clinical indications for breast MRI, breast lump presented 28.2% of indications, breast prosthesis control accounted for 11.7%, family history of cancer 11.7%, breast cancer control 9.4%, post-treatment control 8.4%, screening 6.5%, breast cancer follow-up 5.5%, dense breast 5.5%, family history of cancer and nodule 4.9%, preoperative 3.2%, asymmetry 2.3%, microcalcifications 1.3%, and breast cancer mutation 1.0%. In the Bi-Rads classification, higher percentage for Bi-Rads 2 represented 49.8% and Bi-Rads 3 with a frequency of 27%; Bi-Rads 4 represented 13.4%, Bi-Rads 6 with 5.5%, Bi-Rads 1 with 3.3%, and Bi-Rads 5 represented 1.0% of the classifications of the medical reports. Conclusion: This study showed the predominant age group of the women who attended was 40–49 years, and the most prevalent clinical indication for breast MRI was breast lump.
APA, Harvard, Vancouver, ISO, and other styles
5

Bromberg, Silvio E., Patricia R. A. F. Moraes, and Paulo G. T. Amaral. "COMPARING CONVENTIONAL BREAST CONSERVING SURGERY WITH THE MINIMALLY INVASIVE APPROACH TECHNIQUE TO TREAT EARLY BREAST CANCER - A RETROSPECTIVE CASE CONTROL STUDY." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1ep25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Thiesen, Ana Paula, Bruna Mielczarski, and Ricardo Francalacci Savaris. "DEEP LEARNING NEURAL NETWORK IMAGE ANALYSIS OF IMMUNOHISTOCHEMICAL PROTEIN EXPRESSION REVEALS A SIGNIFICANTLY REDUCED EXPRESSION OF BIGLYCAN IN BREAST CANCER." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2014.

Full text
Abstract:
Objective: The aim of this study was to compare the protein expression of biglycan (BGN) in normal breast tissue and in breast cancer using deep learning and digital HScore techniques. Methods: In this case-control study, 24 formalin-fixed, paraffin-embedded tissues were obtained from pathological archives for analysis. Normal breast (n=9) and breast cancer (n=15) tissue sections were analyzed by immunohistochemistry using BGN monoclonal antibody (M01 – Abnova), clone 4E1-1G7 at dilution 1:300 at pH 6, and 3,3’-diaminobenzidine (DAB) as the chromogen. Photomicrographs of the slides were analyzed using the ImageJ software with “color deconvolution”. After selecting the regions of interest (ROI), deconvoluted panels with DAB only were quantified using arbitrary DAB units. Another set, with higher magnification without ROI selection, was submitted to the inception V3 deep neural network image embedding recognition model. Next, supervised neural network analysis, using stratified 20-fold cross-validation, with 200 hidden layers, ReLu activation, and regularization at α=0.0001 were applied for SDLNN. The sample size was calculated for a minimum of seven cases and seven controls, having a power of 90%, an α error=5%, and a standard deviation of 20, to identify a decrease from the average of 40 DAB units (control) to 4 DAB units in cancer. Ethical approval was obtained from the Hospital de Clínicas de Porto Alegre Ethical Review Board (2019/0337). CAAE 15329119.9.0000.5327. Results: BGN expression (mean±SD) was 6.1±3.9 in breast cancer tissue, while in normal breast tissue, it was 39.6±21.9, using D-HScore (p=0.0017, student t-test, Welch corrected). SDLNN was able to correctly classify 110 out of 129 photomicrographs of the dataset using DAB panels only, with a classification accuracy of 85.3% (95%CI 78.1–90.3%) and the area under the curve of 94.3%. Conclusion: D-HScore and SDLNN revealed that BGN protein expression is reduced in breast cancer tissue, compared to normal tissue. The use of SDLNN seems to be a potential tool for image analysis in histological samples.
APA, Harvard, Vancouver, ISO, and other styles
7

Sivasankaran, Nivetha. "Biosensor and breast cancer treatment." In 2015 International Conference on Robotics, Automation, Control and Embedded Systems (RACE). IEEE, 2015. http://dx.doi.org/10.1109/race.2015.7097239.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Silveira, Letícia Andrade, Beatriz Santos da Paz, Thamara Rafaella Costa de Jesus, and Marcus de Souza Alves. "THE INFLUENCE OF PHYSICAL EXERCISE AS INTEGRATIVE, COMPLEMENTARY PRACTICE ON PATIENTS WITH BREAST CANCER DIAGNOSTIC: A LITERATURE REVIEW." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2058.

Full text
Abstract:
Objective: The aim of this study was to evaluate the influence of physical exercise as an alternative to integrative and complementary practices and its importance in patients diagnosed with breast cancer. Methods: This is a literature review that was carried out in the PubMed and SciELO databases, in which the articles were searched using the following terms: breast cancer, physical exercise, quality of life, and nonpharmacological treatment, selected between the period of 2017 and 2022. The types of study selected for research were experimental and observational. Results: A study carried out with 28 patients was divided into an experimental group (combined and hospital treatment) and a control group (hospital treatment), where it was concluded that the combined treatment (aerobic, resistance, and flexibility exercise) led to an increase in the frequency of physical activity. Physical exercise in patients with breast cancer provides better cardiorespiratory and joint control. In another study that was carried out with 10 women who survived breast cancer, for 4 months, with the practice of combined physical exercises, it was evidenced that remotely supervised non-face-to-face aerobic and resistance exercises can help maintain the level of fatigue positively. These results corroborate the perception of professionals from the Family Health Strategy, who observed the positive effects of complementary integrative practices (PICS) through the suffering and fragility in the treatment of women with breast cancer, acting on an emotional and spiritual improvement for them, which makes these practices relevant adjunct to conventional treatment in primary care. Conclusion: Physical exercise as an integrative practice can improve asthenia, assist in cardiorespiratory and joint control, and aid in the management of fatigue. Therefore, PICS provides emotional, physical, and spiritual benefits for patients diagnosed with breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
9

K.P., Adila, and Sheeba K. "Feature fused breast cancer detection." In 2020 International Conference on Futuristic Technologies in Control Systems & Renewable Energy (ICFCR). IEEE, 2020. http://dx.doi.org/10.1109/icfcr50903.2020.9249995.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gonçalves, Heloísa Helena Rengel, Mariana Burity Xavier, Alfredo Carlos Simões Dornellas de Barros, Graziela Couto de Carvalho, and Larissa Scarabucci Venezian. "ASSOCIATION BETWEEN LEVONORGESTRELRELEASING INTRAUTERINE SYSTEM AND BREAST CANCER." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1005.

Full text
Abstract:
Introduction: The association between the use of hormonal contraception and breast cancer has been debated in the medical community for years. Although older studies have suggested an increase in breast cancer risk with the use of combined oral contraceptive (COC) pills, more recent studies have demonstrated the relative safety of combined contraceptives composed of estrogen and progesterone. Isolated progestagens are usually prescribed to women who have menstrual cycle disturbances; however, literature on the association between the use of isolated progestagens and breast cancer is still controversial. The levonorgestrel intrauterine system (LNG-IUS) device is a long-duration, reversible contraceptive. It has become popular due to its high efficacy as a birth control method and other beneficial effects, such as control of abnormal uterine bleeding and endometrial protection. Nevertheless, its safety regarding breast cancer has is still questioned. Furthermore, it has been debated whether it would be a viable choice for birth control for breast cancer survivors, as well as a tool for endometrial protection among women who use tamoxifen, which leads to endometrial thickening, polyps, and even hyperplasia and endometrial cancer. Objective: This study aims to present a literary review of the main articles within the theme of the use of LNG-IUS and its safety for breast cancer survivors and in the general population. Methods: A literature review was conducted for articles with this theme, using an electronic library, with predetermined keywords. Results: In total, 25 articles were selected that fulfilled the inclusion criteria. Progesterone has a proliferative effect on the breast during the luteal phase of the menstrual cycle, in addition to inducing alveologenesis during puberty and ductal branching during pregnancy. This proliferative effect takes place through the expression of cyclin D1 on nPR-expressing cells. Moreover, it presents a paracrine effect on the adjacent cells that do not express hormone receptors, through the activation of membrane receptors that activate the nuclear factor kappa beta — the receptor activator of NF-κβ (RANK). Studies with animals showed that carcinogenesis was accelerated after the administration of progestagens, mediated by RANK ligands (RANKL). It is also known that levonorgestrel has an action on the 17-betahydroxysteroid dehydrogenase (17β-HSDs) enzymes on T47D epithelial breast carcinoma cells, increasing the bioactivity of estrogen on these cells. Comparing the use of LNG-IUS with the use of levonorgestrel orally, users of LNG-IUS have significantly lower levonorgestrel serum levels. Some populational studies have evaluated the association of LNG-IUS use and the risk of breast cancer, with discordant results. In some studies, for women who have used LNG-IUS, the risk was up to 73% higher. Regarding its safety for breast cancer survivors using tamoxifen, it has been shown that there is little or no difference in breast cancer recurrence with the use of LNG-IUS. However, other authors claim that there are not enough data to confirm the safety concerning breast cancer recurrence, and its use may lead to irregular bleeding and invasive procedures to assess the endometrial layer. Conclusion: In populational studies, the use of LNG-IUS increases breast cancer risk. In breast cancer survivors who use tamoxifen, LNG-IUS seems to protect the endometrium, but more studies are necessary to confirm its safety for breast cancer recurrence.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Breast Cancer Control"

1

Williams, Kristin P. Epigenetic Control of Tamoxifen-Resistant Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, January 2013. http://dx.doi.org/10.21236/ada581650.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Williams, Kristin P. Epigenetic Control of Tamoxifen-Resistant Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, March 2014. http://dx.doi.org/10.21236/ada601260.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Ying yuan, Zechang Chen, Luxin Zhang, Shuangyi Chen, Zhuomiao Ye, Tingting Xu, and Yingying Zhang c. A systematic review and network meta-analysis: Role of SNPs in predicting breast carcinoma risk. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0092.

Full text
Abstract:
Review question / Objective: P: Breast cancer patient; I: Single nucleotide polymorphisms associated with breast cancer risk; C: Healthy person; O: By comparing the proportion of SNP mutations in the tumor group and the control group, the effect of BREAST cancer risk-related SNP was investigated; S: Case-control study. Condition being studied: Breast cancer (BC) is one of the most common cancers among women, and its morbidity and mortality have continued to increase worldwide in recent years, reflecting the strong invasiveness and metastasis characteristics of this cancer. BC is a complex disease that involves a sequence of genetic, epigenetic, and phenotypic changes. Polymorphisms of genes involved in multiple biological pathways have been identified as potential risks of BC. These genetic polymorphisms further lead to differences in disease susceptibility and severity among individuals. The development of accurate molecular diagnoses and biological indicators of prognosis are crucial for individualized and precise treatment of BC patients.
APA, Harvard, Vancouver, ISO, and other styles
4

Brogan, Donna J. Methodology for Case-Control Studies of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 1996. http://dx.doi.org/10.21236/ada333387.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hinds, Phillip W. Function of Cell Cycle Control Proteins in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 1997. http://dx.doi.org/10.21236/ada334893.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hinds, Philip W. Function of Cell Cycle Control Proteins in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 1995. http://dx.doi.org/10.21236/ada300314.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hinds, Phillip W. Function of Cell Cycle Control Proteins in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 1998. http://dx.doi.org/10.21236/ada359618.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Aldaz, Claudio M. The p16 Pathway in Breast Cancer and Senescence Control. Fort Belvoir, VA: Defense Technical Information Center, September 2000. http://dx.doi.org/10.21236/ada391851.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Aldaz, Claudio M. The p16 Pathway in Breast Cancer and Senescence Control. Fort Belvoir, VA: Defense Technical Information Center, September 1999. http://dx.doi.org/10.21236/ada383067.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Holmes, Chris E. Platelet Modulation in the Control of Breast Cancer Angiogenesis and Metastasis. Fort Belvoir, VA: Defense Technical Information Center, October 2009. http://dx.doi.org/10.21236/ada520031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Breast Cancer Control' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography